You searched for: canileish (Engelska - Litauiska)

canileish lyophilisate
canileish liofilizatas

what is canileish?
kas yra canileish?

how does canileish work?
kaip veikia canileish?

canileish is a vaccine.
canileish yra vakcina.

what is canileish used for?
kam naudojamas canileish?

how has canileish been studied?
kaip buvo tiriamas canileish?

other information about canileish:
kita informacija apie canileish:

what is the risk associated with canileish?
kokia rizika siejama su canileish naudojimu?

what benefit has canileish shown during the studies?
kokia canileish nauda nustatyta tyrimuose?

canileish lyophilisate and solvent for suspension for injection for dogs
canileish liofilizatas ir skiediklis injekcinei suspensijai ruošti šunims

canileish is to be used only in ‘leishmania-negative’ dogs.
canileish galima skirti tik leišmanioze nesergantiems šunims.

canileish is a vaccine that contains a number of proteins that are released from the leishmania infantum parasite during its growth.
canileish vakcinos sudėtyje yra įvairių baltymų, kuriuos augdamas išskiria leishmania infantum parazitas.

canileish is used to vaccinate dogs from six months of age to reduce the risk of developing an active infection and clinical disease after contact with leishmania infantum.
canileish skiriamas šunims nuo 6 mėnesių vakcinuoti, siekiant sumažinti aktyvios infekcijos ir klinikinės ligos išsivystymo riziką po kontakto su leishmania infantum.

canileish contains an ‘adjuvant’ (a highly purified fraction of quillaja saponaria) to enhance the immune response.
canileish sudėtyje yra adjuvanto (itin gerai išgryninta quillaja saponaria dalis) imuninei reakcijai sustiprinti.

the european commission granted a marketing authorisation valid throughout the european union, for canileish to virbac s.a. on 14/03/2011.
europos komisija 2011 03 14 bendrovei „virback s.a.“ suteikė visoje europos sąjungoje galiojančią canileish rinkodaros teisę.

the cvmp concluded that the benefits of canileish outweigh the risks for the active immunisation of leishmania-negative dogs from six months of age to reduce the risk to develop an active infection and clinical disease after contact with leishmania infantum and recommended that canileish be given a marketing authorisation.
cvmp nusprendė, kad canileish nauda yra didesnė už keliamą riziką leišmanijomis neužsikrėtusiems šunims nuo 6 mėn. amžiaus aktyviai imunizuoti, siekiant sumažinti leišmanijų sukeliamos aktyvios infekcijos ir klinikinės ligos išsivystymo riziką po kontakto su leishmania infantum, ir rekomendavo suteikti canileish rinkodaros teisę.

any person intending to import, sell, supply and/or use canileish must consult the relevant member state’s competent authority on the current vaccination policies prior to the import, sale, supply and/or use.
asmenys, ketinantys importuoti, parduoti, tiekti ir (arba) naudoti canileish, turi sužinoti atitinkamos es šalies kompetentingos institucijos galiojančią vakcinavimo strategiją.